- Home
- TSI vs GNFT Comparison
TSI vs GNFT Comparison
Compare TSI & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- GNFT
- Stock Information
- Founded
- TSI 1987
- GNFT 1999
- Country
- TSI United States
- GNFT France
- Employees
- TSI N/A
- GNFT N/A
- Industry
- TSI Investment Managers
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TSI Finance
- GNFT Health Care
- Exchange
- TSI Nasdaq
- GNFT Nasdaq
- Market Cap
- TSI 244.7M
- GNFT 249.0M
- IPO Year
- TSI N/A
- GNFT 2019
- Fundamental
- Price
- TSI $5.03
- GNFT $5.39
- Analyst Decision
- TSI
- GNFT Strong Buy
- Analyst Count
- TSI 0
- GNFT 1
- Target Price
- TSI N/A
- GNFT $13.00
- AVG Volume (30 Days)
- TSI 106.8K
- GNFT 20.1K
- Earning Date
- TSI 01-01-0001
- GNFT 09-19-2024
- Dividend Yield
- TSI 7.46%
- GNFT N/A
- EPS Growth
- TSI N/A
- GNFT N/A
- EPS
- TSI N/A
- GNFT 0.47
- Revenue
- TSI N/A
- GNFT $86,225,222.00
- Revenue This Year
- TSI N/A
- GNFT $155.44
- Revenue Next Year
- TSI N/A
- GNFT N/A
- P/E Ratio
- TSI N/A
- GNFT $11.07
- Revenue Growth
- TSI N/A
- GNFT 175.45
- 52 Week Low
- TSI $4.48
- GNFT $2.89
- 52 Week High
- TSI $4.87
- GNFT $6.05
- Technical
- Relative Strength Index (RSI)
- TSI 38.20
- GNFT 60.67
- Support Level
- TSI $5.05
- GNFT $5.06
- Resistance Level
- TSI $5.16
- GNFT $6.05
- Average True Range (ATR)
- TSI 0.06
- GNFT 0.31
- MACD
- TSI -0.02
- GNFT 0.04
- Stochastic Oscillator
- TSI 2.63
- GNFT 65.60
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment, and others.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.